Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA Approves Eylea for Diabetic Retinopathy

The U.S. FDA approved Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) Injection for all stages of diabetic retinopathy, which is the leading cause of vision loss in diabetic patients.

Read More »

Novartis buys dry-eye drug from Takeda for up to $5.3 billion

Novartis is buying the projected blockbuster dry-eye drug Xiidra from Takeda Pharmaceutical for up to $5.3 billion.

Read More »

Future of Healthcare

I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.

Read More »

Novartis Announces FDA Filing Scceptance, Priority Review Of Brolucizumab For Patients With Wet AMD

Novartis announced that the U.S. Food and Drug Administration accepted the company’s Biologics License Application for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration.

Read More »

A Clearer Vision for Gene Therapies: Gyroscope and Orbit Biomedical Merge

Gyroscope Therapeutics – with headquarters in Stevenage, UK – is merging with Ambler, Pennsylvania-based Orbit Biomedical. The companies will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.

Read More »

Contact lenses that reduce eye itch may become a reality

Experimental contact lenses that not only improve vision, but also ward off itchiness due to allergies, got a boost with the completion of two late-stage studies, according to a new report.

Read More »

Aldeyra’s eye drug meets main goal in late-stage study

Aldeyra Therapeutics Inc.’s drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.

Read More »

Alcon Acquires PowerVision for $285 Million

Alcon, the eye care division of Novartis, acquired fluid-based intraocular lens maker PowerVision Inc. for $285 million.

Read More »

U.S. FDA Approves Rocklatan 0.02%/0.005% for Reduction of Intraocular Pressure

Aerie Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration approved Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Read More »

Roche Study Shows Artificial Intelligence Can Detect Severity Of Diabetic Macular Edema

A new study shows first-time proof that AI can detect the severity of diabetic macular edema, which is a leading cause of blindness.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom